



B) SARS-CoV-2 (pre-B.1.1.7 variants)



naturally acquired immunity to SARS-CoV-2

C) SARS-CoV-2 (B.1.1.7)



naturally acquired immunity to SARS-CoV-2

Vaccine effectiveness (%) 50 70 90